Skip to main content
Premium Trial:

Request an Annual Quote

Cyclacel Initiates Public/Private RNAi Technology Alliance

NEW YORK, March 31 - Cyclacel said today that it has entered a four-way collaboration with several private and public partners to develop RNA interference (RNAi) technology for target validation and drug discovery. 

 

Cyclacel will be working with "one of the world's top five pharmaceutical companies," UK-based tech transfer agency Cancer Research Technology Limited (CRT), and the University of Cambridge to improve RNAi technology for use in analyzing gene expression in mammalian cells.

 

The four parties have "combined their intellectual property and skills," according to a Cyclacel statement, to jointly develop the use of the RNAi technique as a tool in target validation, drug discovery, and development. Each of the partners will apply the technology developed under the collaboration to their own drug discovery research projects. In addition, CRT retains the right to commercialize "certain technologies" discovered by the collaboration via third parties. Cyclacel and the undisclosed pharmaceutical company would be eligible to receive royalties from any commercial products.

 

David Glover, chief scientist of Cyclacel's Polgen division, will lead the RNAi research. Polgen uses RNAi to screen the Drosophila genome to identify genes involved in the mitotic process, and subsequently identify comparable genes in humans that are then investigated as potential druggable targets.

 

Glover is the named inventor on a family of patents that CRT holds on the use of RNAi in mammalian cells. 

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.